These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17826303)

  • 21. Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial.
    Hsieh JC; Hsu CL; Ng SH; Wang CH; Lee KD; Lu CH; Chang YF; Hsieh RK; Yeh KH; Hsiao CH; Chen SY; Shiau CY; Wang HM
    Jpn J Clin Oncol; 2015 Sep; 45(9):819-27. PubMed ID: 26056323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
    Chen X; Liang W; Wan N; Zhang L; Yang Y; Jiang J; Zhang T
    Oral Oncol; 2019 Jul; 94():80-85. PubMed ID: 31178217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promising overall survival of patients with recurrent/metastatic squamous cell carcinoma of head and neck receiving gemcitabine plus cisplatin treatment: report of a multi-center phase II study.
    Yang MH; Chang PM; Tzeng CH; Chang SY; Chu PY; Tai SK; Tsai TL; Wang YF; Huang JL; Wang HM; Chen PM
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):259-65. PubMed ID: 19466409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective study of gemcitabine based chemotherapy for unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy.
    Wang M; Gu J; Wang HX; Wu MH; Li YM; Wang YJ
    Asian Pac J Cancer Prev; 2012; 13(8):4153-6. PubMed ID: 23098537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma.
    Jin Y; Shi YX; Cai XY; Xia XY; Cai YC; Cao Y; Zhang WD; Hu WH; Jiang WQ
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1717-25. PubMed ID: 22684794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience with combination of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
    He X; Ou D; Ying H; Zhu G; Hu C; Liu T
    Eur Arch Otorhinolaryngol; 2012 Mar; 269(3):1027-33. PubMed ID: 21706324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.
    Yang Y; Qu S; Li J; Hu C; Xu M; Li W; Zhou T; Shen L; Wu H; Lang J; Hu G; Luo Z; Fu Z; Qu S; Feng W; Chen X; Lin S; Zhang W; Li X; Sun Y; Lin Z; Lin Q; Lei F; Long J; Hong J; Huang X; Zeng L; Wang P; He X; Zhang B; Yang Q; Zhang X; Zou J; Fang W; Zhang L
    Lancet Oncol; 2021 Aug; 22(8):1162-1174. PubMed ID: 34174189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma.
    Gu MF; Liu LZ; He LJ; Yuan WX; Zhang R; Luo GY; Xu GL; Zhang HM; Yan CX; Li JJ
    Int J Cancer; 2013 Jan; 132(1):215-23. PubMed ID: 22610788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study.
    Kong XY; Lu JX; Yu XW; Zhang J; Xu QL; Zhang RJ; Mi JL; Liao SF; Fan JF; Qin XL; Yao DC; Tang HY; Jiang W
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):155-161. PubMed ID: 31087135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma.
    Jin C; Zheng H; Zhan M; Wen F; Xu T
    Eur Arch Otorhinolaryngol; 2020 Feb; 277(2):577-584. PubMed ID: 31720816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.
    Gao Y; Huang HQ; Bai B; Cai QC; Wang XX; Cai QQ
    Expert Opin Pharmacother; 2014 Feb; 15(2):163-71. PubMed ID: 24295173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
    Sternberg CN; Calabrò F; Pizzocaro G; Marini L; Schnetzer S; Sella A
    Cancer; 2001 Dec; 92(12):2993-8. PubMed ID: 11753976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy.
    Peng PJ; Ou XQ; Chen ZB; Liao H; Peng YL; Wang SY; Zhang HY; Lin Z
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):323-8. PubMed ID: 23728706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma.
    Yang Q; Nie YH; Cai MB; Li ZM; Zhu HB; Tan YR
    Drug Des Devel Ther; 2022; 16():1191-1198. PubMed ID: 35502425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
    Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
    Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma.
    Zhao L; Xu M; Jiang W; Pan H; Zang J; Luo S; Wang J; Zhou Y; Shi M
    Oncotarget; 2017 Jan; 8(4):6763-6774. PubMed ID: 28036270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma.
    Wang CC; Chang JY; Liu TW; Lin CY; Yu YC; Hong RL
    Head Neck; 2006 Jan; 28(1):74-80. PubMed ID: 16331692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck.
    Hitt R; Castellano D; Hidalgo M; García-Carbonero R; Peña M; Brandariz A; Millán JM; Alvarez Vincent JJ; Cortés-Funes H
    Ann Oncol; 1998 Dec; 9(12):1347-9. PubMed ID: 9932167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined chemotherapy with cisplatin, docetaxel and capecitabine for metastatic nasopharyngeal carcinoma: a retrospective analysis.
    Chen SZ; Chen XM; Ding Y; Wang XC; Zhang F; Mo KL
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(7):1114-8. PubMed ID: 21764676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma.
    Li Y; Pan K; Liu LZ; Li YQ; Gu MF; Zhang H; Shen WX; Xia JC; Li JJ
    PLoS One; 2015; 10(6):e0130620. PubMed ID: 26098948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.